Tg Therapeutics, INC

TG Therapeutics reported robust second quarter 2026 results, driven by significant BRIUMVI revenue growth, leading to an upward revision of full-year financial targets.

TG Therapeutics shareholders re-elected all six director nominees but rejected the advisory vote on executive compensation.

TG Therapeutics announced positive Phase 1 data for its subcutaneous BRIUMVI formulation, supporting quarterly dosing and potentially expanding market opportunity for multiple sclerosis treatment.

TG Therapeutics reports positive topline results from its Phase 3 ENHANCE trial, demonstrating bioequivalence for a consolidated single infusion regimen of BRIUMVI in relapsing forms of multiple sclerosis.

TG Therapeutics reported strong first quarter 2026 results, exceeding expectations with significant BRIUMVI revenue and raising full-year financial guidance.

TG Therapeutics, Inc. has amended its financing agreement, securing a new $750 million term loan facility and an uncommitted $250 million additional facility.

TG Therapeutics refinanced its debt with a new $750 million credit facility, adding $500 million in non-dilutive capital, and increased its share repurchase program to $300 million, while reporting strong Q1 2026 revenue growth.

TG Therapeutics announced a significant increase in product revenue and net income for the nine months ended September 30, 2025, driven by strong BRIUMVI sales and a substantial tax benefit.

TG Therapeutics reported significant revenue growth and a return to profitability in Q2 2025, driven by strong BRIUMVI sales and pipeline advancements.

TG Therapeutics achieves profitability in Q1 2025, driven by strong sales of BRIUMVI, its multiple sclerosis treatment.

TG Therapeutics reports a profitable third quarter in 2024, driven by strong Briumvi sales and strategic licensing agreements, while also highlighting ongoing clinical development programs.

TG Therapeutics reports a profitable second quarter driven by strong Briumvi sales and secures a new $250 million credit facility.

TG Therapeutics' 2025 annual report reveals robust revenue growth driven by BRIUMVI, achieving substantial net income and advancing its key pipeline assets.

TG Therapeutics' 2024 10-K filing highlights successful BRIUMVI commercialization, pipeline expansion, and a transition to profitability.

TG Therapeutics is amending its annual report on Form 10-K for the fiscal year ended December 31, 2023, to address a material weakness identified in its internal control over financial reporting related to share-based payment awards.

TG Therapeutics reports a profitable 2023 driven by BRIUMVI sales and a significant licensing deal, while also expanding its pipeline with a new CAR-T therapy program.

TG Therapeutics Director Sagar Lonial acquired 8,325 Stock Tracking Units on June 11, 2026, which vest on the first anniversary of the grant date.

TG Therapeutics, Inc. reports that Director Daniel Hume acquired 8,325 Stock Tracking Units on June 11, 2026, which vest on the first anniversary of the grant date.

Kenneth Hoberman, a Director at TG Therapeutics, Inc., acquired 8,325 Stock Tracking Units on June 11, 2026, with vesting contingent on continued service.

TG Therapeutics Director Yann Echelard acquired 8,325 Stock Tracking Units on June 11, 2026, as disclosed in a Form 4 filing.

Laurence N. Charney, a Director at TG Therapeutics, Inc., acquired 8,325 Stock Tracking Units on June 11, 2026, with vesting contingent on continued service.

TG Therapeutics Director Laurence N. Charney gifted a total of 43,197 shares of common stock to his children in late January 2026.

TG Therapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 11, 2026.

TG Therapeutics has filed a definitive proxy statement with the SEC, related to its upcoming shareholder meeting.

TG Therapeutics is asking stockholders to approve an amendment to its 2022 Incentive Plan, increasing the number of shares authorized for issuance from 17,000,000 to 22,000,000.

TG Therapeutics has filed a definitive proxy statement with the SEC.

TG Therapeutics is asking stockholders to approve amendments to its Certificate of Incorporation to increase authorized common stock and to its 2022 Incentive Plan to remove the full-value awards limit at the upcoming Annual Meeting on June 14, 2024.

Vanguard Portfolio Management has reported beneficial ownership of 5.26% of TG Therapeutics Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in TG Therapeutics Inc. following an internal realignment.

State Street Corporation has reported a 5.1% beneficial ownership stake in TG Therapeutics Inc., totaling 8,100,619 shares of common stock.

State Street Corporation has reported a 4.7% beneficial ownership stake in TG Therapeutics Inc., held for investment purposes without intent to influence control.

BlackRock, Inc. has filed an updated Schedule 13G, revealing a 12.8% beneficial ownership stake in TG Therapeutics, Inc. as of March 31, 2025.

The Vanguard Group has reported a 10.01% beneficial ownership stake in TG Therapeutics Inc, holding 15,596,480 shares as of December 31, 2024, for passive investment purposes.